On the HCPLive news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.
Two-Year Data Shows Deucravacitinib Safe, Efficacious in Moderate to Severe Plaque Psoriasis
May 12th 2022These new data come as the FDA reviews the new drug application for deucravacitinib which, if approved, would make deucravacitinib the first allosteric tyrosine kinase 2 inhibitor approved for any disease.